Insider Trading Review: RXi Pharmaceuticals Corporation $RXII

9591645d5db6965a33bff4261d5e21e2

RXi Pharmaceuticals Corporation (RXII) insider have most recently took part in a trading activity. On Jun 23, 2017 Dispersyn Gerrit, Chief Development Officer bought 3,500 shares having total worth of $2,170 at the price of $0.62 per share, following the transaction a total of 3,500 shares owned by Dispersyn Gerrit.

The stock has experienced a total of 2 insider trades in the past three months. These trades include 2 buy trades. Furthermore, over the past 12 months , the stock was traded 7 times by insiders. an employee of the company was the buyer in 7 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 2 0 -17.89%
12 Month 7 0 -77.72%

Shares of RXi Pharmaceuticals Corporation (RXII) traded down 1.73% on Jun 23, 2017, hitting $0.62. 139,218 shares of the company’s stock traded hands. RXi Pharmaceuticals Corporation has a 52 week low of $0.54 and a 52 week high of $3.24. The company’s market cap is $13 million.

RXi Pharmaceuticals Corporation (RXII) last announced its earnings results on May 11, 2017. The company reported -0.12 earnings per share (EPS) for the quarter. During the same quarter in the previous year, the company posted -0.34 earnings per share. The company’s revenue for the quarter was down 100% on a year-over-year basis.

2017-05-11 2017-03-30 2016-11-10 2016-08-11 2016-05-12 2016-03-30 2015-11-12 2015-08-12 2015-05-13 2015-03-30
earnings per share -0.12 -0.60 -0.34 -0.34 -0.34 -0.04 -0.04 -0.05 -0.13 -0.13
Revenue(M) 0 0 0 0.01 0.01 0 0 0 0.03 0.01

RXi Pharmaceuticals Corp was incorporated in Delaware as a wholly owned subsidiary of Galena on September 8, 2011 in preparation for its planned spin-off from Galena, which was completed on April 27, 2012. The Company is a biotechnology company. Its main business activities are discovering, developing and commercializing therapies based on its proprietary, new-generation RNA interference platform. Its proprietary therapeutic platform is comprised of novel RNAi compounds, referred to as rxRNA compounds. It has developed a number of unique forms of rxRNA compounds, all of which have been shown to be potent both in vitro and in preclinical in vivo models. These RNAi compounds include rxRNAori and sd-rxRNA, or ‘self-delivering’ RNA. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.